Literature DB >> 11994495

Characterization of drug-specific T cells in phenobarbital-induced eruption.

Hideo Hashizume1, Masahiro Takigawa, Yoshiki Tokura.   

Abstract

Phenobarbital has a high potential to elicit adverse reactions including severe skin eruptions and systemic involvements among the worldwide-prescribed drugs. Although phenobarbital hypersensitivity is thought to be mediated by T cells specific to the drug, its precise mechanism remains not fully elucidated. To characterize T cells reactive with phenobarbital, we generated drug-specific T cell clones and lines from PBMCs of patients with phenobarbital hypersensitivity showing various degrees of cutaneous and extracutaneous involvements. Although the TCR Vbeta repertoire and phenotype in the T cell clones/T cell lines were heterogeneous among the patients, Vbeta13.1(+) and Vbeta5.1(+) clones or lines were raised from the individuals examined who possessed different HLA haplotypes. Histopathological examination suggested that Vbeta5.1(+)CD8(+) T cells and Vbeta13.1(+) T cells played a role in cutaneous and extracutaneous involvements, respectively. A Vbeta13.1(+)CD4(+) clone was found to proliferate in response to the Ag with processing-impaired, fixed APCs. Most of the clones and lines belonged to the Th2 phenotype, producing IL-4 and IL-5 but not IFN-gamma upon phenobarbital stimulation. Clones/lines with Th1 or Th0 phenotypes also constituted minor populations. These observations clearly indicate the heterogeneity and a marked individual deviation of reactive T cell subsets among the patients in terms of CD4/8 phenotype, Vbeta repertoire, Ag recognition pattern, and cytokine production; and thus provide evidence whereby each pathogenic T cell subset contributes to special elements of clinical presentation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11994495     DOI: 10.4049/jimmunol.168.10.5359

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Preferential infiltration of interleukin-4-producing CXCR4+ T cells in the lesional muscle but not skin of patients with dermatomyositis.

Authors:  T Fujiyama; T Ito; N Ogawa; T Suda; Y Tokura; H Hashizume
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

2.  Type 1 diabetes mellitus in a child with phenobarbital hypersensitivity syndrome.

Authors:  C C Zou; L Liang; J F Fu
Journal:  J Endocrinol Invest       Date:  2008-04       Impact factor: 4.256

Review 3.  In vitro testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review.

Authors:  Abdelbaset A Elzagallaai; Sandra R Knowles; Michael J Rieder; John R Bend; Neil H Shear; Gideon Koren
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

4.  Mass spectrometric characterization of circulating and functional antigens derived from piperacillin in patients with cystic fibrosis.

Authors:  Paul Whitaker; Xiaoli Meng; Sidonie N Lavergne; Sabah El-Ghaiesh; Manal Monshi; Caroline Earnshaw; Daniel Peckham; Jimmy Gooi; Steve Conway; Munir Pirmohamed; Rosalind E Jenkins; Dean J Naisbitt; B Kevin Park
Journal:  J Immunol       Date:  2011-05-23       Impact factor: 5.422

5.  The Effect of Inhibitory Signals on the Priming of Drug Hapten-Specific T Cells That Express Distinct Vβ Receptors.

Authors:  Andrew Gibson; Lee Faulkner; Maike Lichtenfels; Monday Ogese; Zaid Al-Attar; Ana Alfirevic; Philipp R Esser; Stefan F Martin; Munir Pirmohamed; B Kevin Park; Dean J Naisbitt
Journal:  J Immunol       Date:  2017-07-07       Impact factor: 5.422

Review 6.  Idiosyncratic adverse drug reactions: current concepts.

Authors:  Jack Uetrecht; Dean J Naisbitt
Journal:  Pharmacol Rev       Date:  2013-03-08       Impact factor: 25.468

7.  Recent progress of elucidating the mechanisms of drug hypersensitivity.

Authors:  Hideo Hashizume
Journal:  Asia Pac Allergy       Date:  2012-07-25

Review 8.  Immunopharmacology of hypersensitivity reactions to drugs.

Authors:  Dean J Naisbitt; Munir Pirmohamed; B Kevin Park
Journal:  Curr Allergy Asthma Rep       Date:  2003-01       Impact factor: 4.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.